Status:
COMPLETED
Modulation of Hyperinflammation in COVID-19
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
COVID-19
SARS
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Current treatment recommendations are based on very limited evidence and reliant on the deployment of pharmacological strategies of doubtful efficacy, high toxicity, and near universal shortages of su...
Detailed Description
The coronavirus disease 2019 (COVID-19) is a novel virus that was first reported in December 2019 from Wuhan, China. So far, over 8,000,000 cases have been reported around the globe with \>400,000 rep...
Eligibility Criteria
Inclusion
- Age greater than or equal to 18 years
- High clinical suspicion of COVID-19 from the opinion of both infectious disease specialist (s) and the ICU team
- Evidence of acute respiratory distress syndrome requiring admission to the Critical Care Trauma Centre Medical Surgical ICU, or the Cardiac Surgical Recovery Unit
- Vasopressor support
Exclusion
- Pregnant
- Unconfirmed COVID-19
- Chronic immune depression
- Contra-indications to regional citrate anticoagulation
Key Trial Info
Start Date :
April 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2024
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04353674
Start Date
April 28 2020
End Date
March 15 2024
Last Update
March 29 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
London, Ontario, Canada, N6A 5A5
2
Victoria Hospital - Critical Care Trauma Centre
London, Ontario, Canada, N6C 2V4